Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 87Other hematologic neoplasm 54Plasma cell 22Breast 18Sarcoma 16Myeloid 14Gastrointestinal 10CNS 9Gynecologic 8Thoracic 6Genitourinary 5Dermatologic 5Classical hematology 4Other solid neoplasm 2Head & Neck 2Endocrine 2Tumor-Agnostic 1NET 1

Conditions

Urogenital Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 8Specimen Handling 5Magnetic Resonance Spectroscopy 5pembrolizumab 3Everolimus 3cabozantinib 2X-Rays 2repotrectinib 1peposertib 1pazopanib 1olaparib 1lenvatinib 1fludarabine 1entrectinib 1belinostat 1aldesleukin 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1Photons 1Phantoms, Imaging 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cyclophosphamide × NET × 30 days × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡